Background Survival analysis is a cornerstone of medical research, enabling the assessment
of clinical outcomes for disease progression and treatment efficiency. Despite its central …

In the last decade, optimized treatment for non-small cell lung cancer had lead to improved
prognosis, but the overall survival is still very short. To further understand the molecular basis …

Multiple studies suggested using different miRNAs as biomarkers for prognosis of
hepatocellular carcinoma (HCC). We aimed to assemble a miRNA expression database from …

Results The entire database incorporates 1,065 gastric carcinoma samples, gene expression
data. Out of 29 established markers, higher expression of BECN1 (HR= 0.68, p= 1.5 E-05), …

Purpose The proper validation of prognostic biomarkers is an important clinical issue in breast
cancer research. MicroRNAs (miRNAs) have emerged as a new class of promising breast …

The validation of prognostic biomarkers in large independent patient cohorts is a major
bottleneck in ovarian cancer research. We implemented an online tool to assess the prognostic …

To date, three molecular markers (ER, PR, and CYP2D6) have been used in clinical setting
to predict the benefit of the anti-estrogen tamoxifen therapy. Our aim was to validate new …

The estrogen receptor (ER)α drives growth in two-thirds of all breast cancers. Several
targeted therapies, collectively termed endocrine therapy, impinge on estrogen-induced ERα …

In the last decades, several gene expression-based predictors of clinical behavior were
developed for breast cancer. A common feature of these is the use of multiple genes to predict …

Breast cancer clinical treatment selection is based on the immunohistochemical determination
of four protein biomarkers: ESR1, PGR, HER2, and MKI67. Our aim was to correlate …